Hoffmann has been vice-chair of Roche since 2006 and a board director since 1996. Among many other roles, he is a trustee of ...

More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.

CNBC's Angelica Peebles talks to Roche Pharma CEO Teresa Graham discusses why we're still in the early stages of the obesity ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) will finalize the acquisition of Poseida Therapeutics (NASDAQ:PSTX), a biopharmaceutical ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...

HK inno.N markets Roches Avastin for cancer treatment in South Korea HK inno.N and Roche forge collaboration to boost cancer ...